Tags

Type your tag names separated by a space and hit enter

Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain.
Pain Med. 2003 Dec; 4(4):321-30.PM

Abstract

OBJECTIVE

To assess the effectiveness and safety of the lidocaine patch 5%, a targeted peripheral analgesic, in the treatment of postherpetic neuralgia, painful diabetic neuropathy, and low back pain patients with incomplete responses to their current analgesic treatment regimen containing gabapentin.

DESIGN

This was a 2-week, open-label, nonrandomized, multicenter pilot trial in the clinical setting. Patients with postherpetic neuralgia, painful diabetic neuropathy, or low back pain with partial responses (average daily pain intensity >4/10) to their current analgesic treatment regimen were included. Treatment consisted of daily application of up to four lidocaine patches to areas of maximal peripheral pain. Effectiveness was evaluated using the Brief Pain Inventory (BPI). Safety was assessed by adverse events, physical and neurologic examinations, vital signs, and clinical laboratory tests.

RESULTS

Significant improvements in BPI measures of pain intensity and pain relief were reported for all groups of patients after 2 weeks of lidocaine patch 5% treatment. Significant improvements in BPI measures of pain interference with general activity, mood, walking ability, normal work, relationships with others, sleep, and enjoyment of life were noted. The lidocaine patch 5% was found to be safe and well tolerated.

CONCLUSIONS

Results of this study highlight the potential advantages achieved with rational polypharmacy using a targeted peripheral analgesic, the lidocaine patch 5%, with centrally acting agents such as the anticonvulsant gabapentin. Controlled trials are warranted to further define the impact of such combination therapy.

Authors+Show Affiliations

Southern Drug Research, Birmingham, Alabama 35205, USA. bwhite@sdr.usNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

14750908

Citation

White, William T., et al. "Lidocaine Patch 5% With Systemic Analgesics Such as Gabapentin: a Rational Polypharmacy Approach for the Treatment of Chronic Pain." Pain Medicine (Malden, Mass.), vol. 4, no. 4, 2003, pp. 321-30.
White WT, Patel N, Drass M, et al. Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain. Pain Med. 2003;4(4):321-30.
White, W. T., Patel, N., Drass, M., & Nalamachu, S. (2003). Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain. Pain Medicine (Malden, Mass.), 4(4), 321-30.
White WT, et al. Lidocaine Patch 5% With Systemic Analgesics Such as Gabapentin: a Rational Polypharmacy Approach for the Treatment of Chronic Pain. Pain Med. 2003;4(4):321-30. PubMed PMID: 14750908.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain. AU - White,William T, AU - Patel,Nileshkumar, AU - Drass,Michael, AU - Nalamachu,Srinivas, PY - 2004/1/31/pubmed PY - 2004/4/14/medline PY - 2004/1/31/entrez SP - 321 EP - 30 JF - Pain medicine (Malden, Mass.) JO - Pain Med VL - 4 IS - 4 N2 - OBJECTIVE: To assess the effectiveness and safety of the lidocaine patch 5%, a targeted peripheral analgesic, in the treatment of postherpetic neuralgia, painful diabetic neuropathy, and low back pain patients with incomplete responses to their current analgesic treatment regimen containing gabapentin. DESIGN: This was a 2-week, open-label, nonrandomized, multicenter pilot trial in the clinical setting. Patients with postherpetic neuralgia, painful diabetic neuropathy, or low back pain with partial responses (average daily pain intensity >4/10) to their current analgesic treatment regimen were included. Treatment consisted of daily application of up to four lidocaine patches to areas of maximal peripheral pain. Effectiveness was evaluated using the Brief Pain Inventory (BPI). Safety was assessed by adverse events, physical and neurologic examinations, vital signs, and clinical laboratory tests. RESULTS: Significant improvements in BPI measures of pain intensity and pain relief were reported for all groups of patients after 2 weeks of lidocaine patch 5% treatment. Significant improvements in BPI measures of pain interference with general activity, mood, walking ability, normal work, relationships with others, sleep, and enjoyment of life were noted. The lidocaine patch 5% was found to be safe and well tolerated. CONCLUSIONS: Results of this study highlight the potential advantages achieved with rational polypharmacy using a targeted peripheral analgesic, the lidocaine patch 5%, with centrally acting agents such as the anticonvulsant gabapentin. Controlled trials are warranted to further define the impact of such combination therapy. SN - 1526-2375 UR - https://www.unboundmedicine.com/medline/citation/14750908/Lidocaine_patch_5_with_systemic_analgesics_such_as_gabapentin:_a_rational_polypharmacy_approach_for_the_treatment_of_chronic_pain_ L2 - https://academic.oup.com/painmedicine/article-lookup/doi/10.1111/j.1526-4637.2003.03045.x DB - PRIME DP - Unbound Medicine ER -